Patritumab Deruxtecan Makes Headway in Early Phase Trials for Patients With Metastatic EGFR+ NSCLC and HER3+ Breast CancerMarch 21st 2023
Patritumab deruxtecan generated activity in patients with metastatic or unresectable EGFR-mutated non–small cell lung cancer and HER3-expressing breast cancer.
Mirvetuximab Soravtansine Offers New Path Forward for Patients with Frα-Positive Platinum-Resistant Ovarian CancerMarch 13th 2023
Kathleen Lutz, RN, NP-BC WH, weighs in on the recent approval of mirvetuximab soravtansine-gynx for patients with folate receptor alpha (Frα)-positive, platinum-resistant ovarian cancer.
Vaginal/Vulvar Symptoms Show Improvement With Lasofoxifene in Postmenopausal Women With ER+/HER2–, ESR1-Mutated Breast Cancer
Lasofoxifene may be helpful in managing vaginal/vulvar symptoms in women with estrogen receptor–positive/HER2-negative breast cancer harboring an ESR1 mutation.
Remote Patient Monitoring for CAR T Demonstrates Feasibility in the Outpatient SettingMarch 10th 2023
During the 2023 Tandem Meeting, Trista Carelock RN, BSN, ONC, BMT-CN, highlighted how her institution leveraged remote patient monitoring to offer outpatient CAR T-cell therapy to patients.
ODAC Votes in Favor Of Polatuzumab Vedotin in Patients With Treatment Naïve LBCLMarch 10th 2023
The FDA’s Oncologic Drugs Advisory Committee voted 11 to 2 in support of the benefit-risk profile displayed by polatuzumab vedotin-piiq in patients with previously untreated large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified.
Opinion: Clear Communication Is A Form Of Patient AdvocacyMarch 9th 2023
We can help our patients feel supported is by providing them with clear information about their treatment plan and what to expect. By doing so, we empower them to take control of their own health.